Scientific exchange · Dr. Oscar Zimmermann

03 Feb 2026 · In person · Dr. Oscar Zimmermann, UCSF Medical Center · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0085—

Capture insight from this engagement

Location: UCSF Medical Center
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

PD-L1 testing turnaround
Comparator checkpoint monotherapy
Duration of response

Scientific content used

irAE management guide

Questions raised

No questions recorded.

Notes

Scientific exchange with thoracic medical oncologist at UCSF Medical Center. Discussed pd-l1 testing turnaround, comparator checkpoint monotherapy, duration of response.

Insights captured (1)

Capture insight

INS-0046Medium
PD-L1 testing turnaround
PD-L1 testing turnaround: practice variation observed reported by thoracic medical oncologist (US).
Archived

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Schedule follow-up in 6 weeks

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 2
Depth of exchange: 3
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0085

Audit history (1)

All create, update and approval events for this record

Time	Action	User	Field	Change	Reason	Source
04 Sept 2026, 16:47 UTC	Create	LOLuis Ortega	progress	Planned → Submitted	—	Integration